Seminars in Nuclear Medicine
Volume 38, Issue 5 , Pages 358-366 , September 2008

Therapeutic Radionuclides: Biophysical and Radiobiologic Principles

  • Amin I. Kassis, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Amin I. Kassis, PhD, Department of Radiology, Harvard Medical School, Armenise Building, 200 Longwood Avenue, Boston, MA 02115.

References 

  1. Walicka MA, Vaidyanathan G, Zalutsky MR, et al. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res. 1998;150:263–268
  2. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994;35:303–316
  3. Kassis AI. The amazing world of Auger electrons. Int J Radiat Biol. 2004;80:789–803
  4. Cole A. Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res. 1969;38:7–33
  5. Kassis AI, Adelstein SJ, Haydock C, et al. Radiotoxicity of 75Se and 35S: theory and application to a cellular model. Radiat Res. 1980;84:407–425
  6. Kassis AI, Adelstein SJ, Haydock C, et al. Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res. 1982;90:362–373
  7. Kassis AI, Sastry KSR, Adelstein SJ. Intracellular localisation of Auger electron emitters: Biophysical dosimetry. Radiat Prot Dosimetry. 1985;13:233–236
  8. Kassis AI, Adelstein SJ. Does nonuniformity of dose have implications for radiation protection?. J Nucl Med. 1992;33:384–387
  9. Barendsen GW. LET dependence of linear and quadratic terms in dose-response relationships for cellular damage: Correlations with the dimensions and structures of biological targets. Radiat Prot Dosimetry. 1990;31:235–239
  10. Azzam EI, de Toledo SM, Little JB. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from α-particle irradiated to nonirradiated cells. Proc Natl Acad Sci USA. 2001;98:473–478
  11. Narayanan PK, Goodwin EH, Lehnert BE. α particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res. 1997;57:3963–3971
  12. Narayanan PK, LaRue KEA, Goodwin EH, et al. Alpha particles induce the production of interleukin-8 by human cells. Radiat Res. 1999;152:57–63
  13. Iyer R, Lehnert BE. Factors underlying the cell growth-related bystander responses to α particles. Cancer Res. 2000;60:1290–1298
  14. Kishikawa H, Wang K, Adelstein SJ, et al. Inhibitory and stimulatory bystander effects are differentially induced by iodine-125 and iodine-123. Radiat Res. 2006;165:688–694
  15. Sgouros G, Knox SJ, Joiner MC, et al. MIRD continuing education: Bystander and low–dose-rate effects: Are these relevant to radionuclide therapy?. J Nucl Med. 2007;48:1683–1691
  16. Xue LY, Butler NJ, Makrigiorgos GM, et al. Bystander effect produced by radiolabeled tumor cells in vivo.. Proc Natl Acad Sci USA. 2002;99:13765–13770
  17. Boyd M, Ross SC, Dorrens J, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and Auger electron–emitting radionuclides. J Nucl Med. 2006;47:1007–1015
  18. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75–83
  19. Humm JL, Chin LM, Cobb L, et al. Microdosimetry in radioimmunotherapy. Radiat Prot Dosimetry. 1990;31:433–436
  20. International Commission on Radiation Units and Measurements: Absorbed-Dose Specification in Nuclear Medicine, Report 67. J ICRU. 2002;2:1–110
  21. O'Donoghue JA. The impact of tumor cell proliferation in radioimmunotherapy. Cancer. 1994;73:974–980
  22. Kocher DC. Radioactive Decay Data Tables: A Handbook of Decay Data for Application to Radiation Dosimetry and Radiological Assessments. Vol DOE/TIC-11026. Springfield, VA: National Technical Information Center, US Department of Energy; 1981;
  23. International Commission on Radiation Units and Measurements. Stopping Powers and Ranges for Protons and Alpha Particles, Report 49. Bethesda, MD: International Commission on Radiation Units and Measurements; 1993;
  24. Kassis AI, Harris CR, Adelstein SJ, et al. The in vitro radiobiology of astatine-211 decay. Radiat Res. 1986;105:27–36
  25. Charlton DE, Kassis AI, Adelstein SJ. A comparison of experimental and calculated survival curves for V79 cells grown as monolayers or in suspension exposed to alpha irradiation from 212Bi distributed in the growth medium. Radiat Prot Dosimetry. 1994;52:311–315
  26. Chan PC, Lisco E, Lisco H, et al. The radiotoxicity of iodine-125 in mammalian cells (II. A comparative study on cell survival and cytogenetic responses to 125IUdR, 131IUdR, and 3HTdR). Radiat Res. 1976;67:332–343
  27. Bloomer WD, McLaughlin WH, Neirinckx RD, et al. Astatine-211–tellurium radiocolloid cures experimental malignant ascites. Science. 1981;212:340–341
  28. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle–emitting immunoconjugates. Science. 1988;240:1024–1026
  29. Zalutsky MR, McLendon RE, Garg PK, et al. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res. 1994;54:4719–4725
  30. McDevitt MR, Barendswaard E, Ma D, et al. An α-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095–6100
  31. Ballangrud ÅM, Yang W-H, Charlton DE, et al. Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 2001;61:2008–2014
  32. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537–1540
  33. Burki HJ, Koch C, Wolff S. Molecular suicide studies of 125I and 3H disintegration in the DNA of Chinese hamster cells. Curr Top Radiat Res Q. 1977;12:408–425
  34. Esteban JM, Schlom J, Mornex F, et al. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol. 1987;23:643–655
  35. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–418
  36. Chinn PC, Leonard JE, Rosenberg J, et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol. 1999;15:1017–1025
  37. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802–1807
  38. DeNardo GL, Kukis DL, DeNardo SJ, et al. Enhancement of 67Cu-2IT-BAT-Lym-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer. 1997;80:2576–2582
  39. Kassis AI, Sastry KSR, Adelstein SJ. Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: Implications of localized energy deposition by Auger processes. Radiat Res. 1987;109:78–89
  40. Bloomer WD, McLaughlin WH, Weichselbaum RR, et al. Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. Int J Radiat Biol. 1980;38:197–202
  41. Kassis AI, Fayad F, Kinsey BM, et al. Radiotoxicity of 125I in mammalian cells. Radiat Res. 1987;111:305–318
  42. Walicka MA, Ding Y, Roy AM, et al. Cytotoxicity of [125I]iodoHoechst 33342: Contribution of scavengeable effects. Int J Radiat Biol. 1999;75:1579–1587
  43. Costantini DL, Chen C, Cai Z, et al. 111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357–1368
  44. Reske SN, Deisenhofer S, Glatting G, et al. 123I-ITdU–mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, β-, or γ-radiation–resistant cell lines. J Nucl Med. 2007;48:1000–1007
  45. Kassis AI, Kirichian AM, Wang K, et al. Therapeutic potential of 5-[125I]iodo-2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol. 2004;80:941–946
  46. Mariani G, Di Sacco S, Bonini R, et al. Biochemical modulation by 5-fluorouracil and l-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. Acta Oncol. 1996;35:941–945
  47. Bloomer WD, Adelstein SJ. 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature. 1977;265:620–621
  48. Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, et al. 5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys. 1991;21:1541–1551

 Supported by NIH 5 R01 CA015523.

PII: S0001-2998(08)00069-X

doi: 10.1053/j.semnuclmed.2008.05.002

Seminars in Nuclear Medicine
Volume 38, Issue 5 , Pages 358-366 , September 2008

Article Tools

* Image Usage & Resolution